tbuckley/cabot-search huggingface dataset:
Intensivist Consultation and Outcomes in Critically Ill Patients—Reply
Authors: Peter J. Pronovost, Derek C. Angus
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bone Densitometry Testing in Nonwhite Patients
Authors: Max P. Francois, Malcolm D. Reid, William Rosner
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Idiopathic vs Hereditary Pancreatitis—Reply
Authors: F. Ulrich Weiss, Peter Simon, Carsten Hohoff, Klaus Peter Zimmer, Wolfram Domschke, Markus M. Lerch
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Idiopathic vs Hereditary Pancreatitis
Authors: Jian-Min Chen, Claude Férec
Journal: JAMA (2003)

To the Editor: Dr Simon and colleagues report that the hereditary pancreatitis–associated cationic trypsinogen (PRSS1) gene mutation, R122H, was present in 5 (10%) of 50 patients with idiopathic pancreatitis.1 We have a number of concerns about this report.
A new face of old cells: An overview about the role of senescence and telomeres in inflammatory bowel diseases
Authors: Michał Sienkiewicz, Kamila Sroka, Agata Binienda, Diana Jurk, Jakub Fichna
Journal: Ageing Research Reviews (2023)

Cellular senescence is a pivotal factor contributing to aging and the pathophysiology of age-related diseases. Despite the presence of inflammation and abnormal immune system function in both inflammatory bowel diseases (IBD) and senescence, the relationship between the two remains largely unexplored. Therefore, our study aimed to investigate the intricate connection between cellular senescence, telomeres, and IBD. The review highlights the presence of senescence markers, particularly p16 and p21, in IBD patients, suggesting their potential association with disease progression and mucosal inflammation. We emphasize the critical role of macrophages in eliminating senescent cells and how disturbance in effective clearance may contribute to persistent senescence and inflammation in IBD. Additionally, we shed light on the involvement of telomeres in IBD, as their dysfunction impairs enterocyte function and disrupts colonic barrier integrity, potentially exacerbating the pathogenesis of the disease. Targeting senescence and telomere dysfunctions holds promise for the development of innovative therapeutic approaches to mitigate intestinal inflammation and alleviate symptoms in IBD patients. By unraveling the precise role of senescence in IBD, we can pave the way for the discovery of novel therapeutic interventions that effectively address the underlying mechanisms of intestinal inflammation, offering hope for improved management and treatment of IBD patients.
Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention—Correction
Journal: JAMA (2003)

Steven R. Steinhubl, MD; Peter B. Berger, MD; J. Tift Mann III, MD; Edward T. A. Fry, MD; Augustin DeLago, MD; Charles Wilmer, MD; Eric J. Topol, MD; for the CREDO Investigators
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
Authors: William A. Peters, P.Y. Liu, Rolland J. Barrett, Richard J. Stock, Bradley J. Monk, Jonathan S. Berek, Luis Souhami, Perry Grigsby, William Gordon, David S. Alberts
Journal: Journal of Clinical Oncology (2023)

To determine whether the addition of cisplatin-based chemotherapy (CT) to pelvic radiation therapy (RT) will improve the survival of early-stage, high-risk patients with cervical carcinoma.
Flashback Foreword: Concurrent Chemotherapy/Radiotherapy for Cervical Cancer
Authors: Gini F. Fleming
Journal: Journal of Clinical Oncology (2023)

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix. October 05, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00092 Journal of Clinical Oncology - published online before print October 5, 2023 PMID: 37797408 Flashback Foreword: Concurrent Chemotherapy/Radiotherapy for Cervical Cancer Gini F. Fleming , MD1,2xGini F. FlemingSearch for articles by this author Show More 1Associate Editor, Journal of Clinical Oncology, Alexandria, VA2University of Chicago, Chicago, IL https://doi.org/10.1200/JCO.23.00092 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn the companion to this article, Peters et al1 reported that the addition of concomitant chemotherapy to adjuvant radiation therapy in the treatment of women with high-risk factors after radical hysterectomy for cervical cancer significantly improved both progression-free survival and overall survival. This became the standard of care and remains so today.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Concurrent Chemotherapy/Radiotherapy for Cervical CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Gini F. FlemingThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Honoraria: Physicans' Education ResourceResearch Funding: Corcept Therapeutics (Inst), AbbVie (Inst), Iovance Biotherapeutics (Inst), Syros Pharmaceuticals (Inst), Sermonix Pharmaceuticals (Inst), Compugen (Inst), Plexxikon (Inst), Roche (Inst), GlaxoSmithKline (Inst), Celldex (Inst), AstraZeneca (Inst), Molecular Templates (Inst), CytomX Therapeutics (Inst), Astellas Pharma (Inst), K-Group Beta (Inst), Pfizer (Inst), AstraZeneca (Inst), Merck (Inst), Incyte (Inst)Other Relationship: DSI (Inst), Merck (Inst), Caris Life Sciences (Inst), Eisai (Inst), AstraZeneca (Inst)Uncompensated Relationships: AbbVieNo other potential conflicts of interest were reported. Companion Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
External quality assessment of orthohantavirus and lymphocytic choriomeningitis virus molecular detection and serology in Europe, 2021
Authors: Mert Erdin, Kamelia R Stanoeva, Ramona Mögling, Miša Korva, Nataša Knap, Katarina Resman Rus, Cristina Domingo, Johan HJ Reimerink, Ankje de Vries, Hussein Alburkat, Mira Utriainen, Céline M Gossner, Tarja Sironen, Tatjana Avšič-Županc, Chantal BEM Reusken, Olli Vapalahti
Journal: Eurosurveillance (2023)

Background Rodent-borne viruses such as orthohantaviruses and arenaviruses cause considerable disease burden with regional and temporal differences in incidence and clinical awareness. Therefore, it is important to regularly evaluate laboratory diagnostic capabilities, e.g. by external quality assessments (EQA). Aim We wished to evaluate the performance and diagnostic capability of European expert laboratories to detect orthohantaviruses and lymphocytic choriomeningitis virus (LCMV) and human antibody response towards orthohantaviruses. Methods We conducted an EQA in 2021; molecular panels consisted of 12 samples, including different orthohantaviruses (Seoul, Dobrava-Belgrade (DOBV), Puumala (PUUV) and Hantaan orthohantavirus), LCMV and negative controls. Serological panels consisted of six human serum samples reactive to PUUV, DOBV or negative to orthohantaviruses. The EQA was sent to 25 laboratories in 20 countries. Results The accuracy of molecular detection of orthohantaviruses varied (50‒67%, average 62%) among 16 participating laboratories, while LCMV samples were successfully detected in all 11 participating laboratories (91-100%, average 96%). The accuracy of serological diagnosis of acute and past orthohantavirus infections was on average 95% among 20 participating laboratories and 82% in 19 laboratories, respectively. A variety of methods was used, with predominance of in-house assays for molecular tests, and commercial assays for serological ones. Conclusion Serology, the most common tool to diagnose acute orthohantavirus infections, had a high accuracy in this EQA. The molecular detection of orthohantaviruses needs improvement while LCMV detection (performed in fewer laboratories) had 95% accuracy. Further EQAs are recommended to be performed periodically to monitor improvements and challenges in the diagnostics of rodent–borne diseases.
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
Authors: Jingyu Xiang, Jessica M. Devenport, Alun J. Carter, Karl W. Staser, Miriam Y. Kim, Julie O’ Neal, Julie K. Ritchey, Michael P. Rettig, Feng Gao, Garrett Rettig, Rolf Turk, Byung Ha Lee, Matthew L. Cooper, John F. DiPersio
Journal: Leukemia (2023)

Abstract T-cell malignancies are associated with frequent relapse and high morbidity, which is partly due to the lack of effective or targeted treatment options. To broaden the use of CAR-T cells in pan T-cell malignancies, we developed an allogeneic “universal” CD2-targeting CAR-T cell (UCART2), in which the CD2 antigen is deleted to prevent fratricide, and the T-cell receptor is removed to prevent GvHD. UCART2 demonstrated efficacy against T-ALL and CTCL and prolonged the survival of tumor-engrafted NSG mice in vivo. To evaluate the impact of CD2 on CAR-T function, we generated CD19 CAR-T cells (UCART19) with or without CD2 deletion, single-cell secretome analysis revealed that CD2 deletion in UCART19 reduced frequencies of the effector cytokines (Granzyme-B and IFN-γ). We also observed that UCART19ΔCD2 had reduced anti-tumor efficacy compared to UCART19 in a CD19+NALM6 xenograft model. Of note is that the reduced efficacy resulting from CD2 deletion was reversed when combined with rhIL-7-hyFc, a long-acting recombinant human interleukin-7. Treatment with rhIL-7-hyFc prolonged UCART2 persistence and increased survival in both the tumor re-challenge model and primary patient T-ALL model in vivo. Together, these data suggest that allogeneic fratricide-resistant UCART2, in combination with rhIL-7-hyFc, could be a suitable approach for treating T-cell malignancies.
Commentary on ‘Liver resection versus transarterial chemoembolisation for the treatment of intermediate hepatocellular carcinoma: a systematic review and meta-analysis’
Authors: Xin Lu, Yadi Liao, Yubin Liu, Feng Shi
Journal: International Journal of Surgery (2023)

aDepartment of Hepatobiliary Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern medical university, Guangzhou, China bDepartment of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern medical university, Guangzhou, China This article does not refer to any raw data. Xin Lu, Yadi Liao: Both authors contributed equally to this article. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: E-mail address: [email protected] (Y. Liu). *Corresponding author. Address: Guangdong Provincial People's Hospital, CHINA. E-mail address: [email protected] (F. Shi). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Authors: Luis Paz-Ares, Marina Chiara Garassino, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Artem Poltoratskiy, Dmytro Trukhin, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Galina Statsenko, Nikolay Conev, Igor Bondarenko, Libor Havel, György Losonczy, Mingchao Xie, Zhongwu Lai, Nadia Godin-Heymann, Helen Mann, Haiyi Jiang, Yashaswi Shrestha, Jonathan W. Goldman
Journal: Clinical Cancer Research (2023)

In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small cell lung cancer (ES-SCLC). We report exploratory analyses of CASPIAN outcomes by programmed cell death ligand-1 (PD-L1) expression and tissue tumor mutational burden (tTMB).
A commentary on ‘Approved and investigational fluorescent optical imaging agents for disease detection in surgery’
Authors: Si-Un Frank Chiu, Chao-Ming Hung, Chong-Chi Chiu
Journal: International Journal of Surgery (2023)

aDepartment of Computer Science, Brown University, Providence, Rhode Island, USA bDepartment of Economics, Brown University, Providence, Rhode Island, USA cDepartment of General Surgery, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan dSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan eDepartment of Medical Education and Research, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: No.21, Yi-Da Road, Jiao-Su Village, Yan-Chao District, Kaohsiung, 824, Taiwan. Tel.: +886-76150022; fax: +886-76150940. E-mail address: [email protected] (C.-C. Chiu). This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/
From tackles to trauma: investigating the influence of the FIFA World Cup 2022 on public maxillofacial department in Qatar - an observational study
Authors: Afaf K. Hamze, Abdelfatteh El Omri, Ahmed Nouraldeen Derbas, Ismail Dergaa, Gustavo Andrés Grimaldi Finol, Noomen Guelmami, Mohamed Amine Rejeb, Antonio J. Santimano, Kalpana Singh, Omar M. Aboumarzouk, Mustafa Al Khalil
Journal: International Journal of Surgery (2023)

Hamze, Afaf K. MD; El Omri, Abdelfatteh PhD; Derbas, Ahmed Nouraldeen PhD; Dergaa, Ismail PhD; Finol, Gustavo Andrés Grimaldi MD; Guelmami, Noomen PhD; Rejeb, Mohamed Amine MD; Santimano, Antonio J. MD; Singh, Kalpana PhD; Aboumarzouk, Omar M. MD, PhD; Al Khalil, Mustafa MD Author Information
Disrupted Binding of Cystathionine γ-Lyase to p53 Promotes Endothelial Senescence
Authors: Jiong Hu, Matthias S. Leisegang, Mario Looso, Maria-Kyriaki Drekolia, Janina Wittig, Janina Mettner, Christina Karantanou, Anastasia Kyselova, Gabrijela Dumbović, Xiaoming Li, Yuanyuan Li, Stefan Guenther, David John, Mauro Siragusa, Sven Zukunft, James A. Oo, Ilka Wittig, Susanne Hille, Andreas Weigert, Stefan Knapp, Ralf P. Brandes, Oliver J. Müller, Andreas Papapetropoulos, Fragiska Sigala, Gergana Dobreva, Baktybek Kojonazarov, Ingrid Fleming, Sofia-Iris Bibli
Journal: Circulation Research (2023)

BACKGROUND: Advanced age is unequivocally linked to the development of cardiovascular disease; however, the mechanisms resulting in reduced endothelial cell regeneration remain poorly understood. Here, we investigated novel mechanisms involved in endothelial cell senescence that impact endothelial cell transcription and vascular repair after injury. METHODS: Native endothelial cells were isolated from young (20±3.4 years) and aged (80±2.3 years) individuals and subjected to molecular analyses to assess global transcriptional and metabolic changes. In vitro studies were conducted using primary human and murine endothelial cells. A murine aortic re-endothelialization model was used to examine endothelial cell regenerative capacity in vivo. RESULTS: RNA sequencing of native endothelial cells revealed that aging resulted in p53-mediated reprogramming to express senescence-associated genes and suppress glycolysis. Reduced glucose uptake and ATP contributed to attenuated assembly of the telomerase complex, which was required for endothelial cell proliferation. Enhanced p53 activity in aging was linked to its acetylation on K120 due to enhanced activity of the acetyltransferase MOZ (monocytic leukemic zinc finger). Mechanistically, p53 acetylation and translocation were, at least partially, attributed to the loss of the vasoprotective enzyme, CSE (cystathionine γ-lyase). CSE physically anchored p53 in the cytosol to prevent its nuclear translocation and CSE absence inhibited AKT (Protein kinase B)-mediated MOZ phosphorylation, which in turn increased MOZ activity and subsequently p53 acetylation. In mice, the endothelial cell–specific deletion of CSE activated p53, induced premature endothelial senescence, and arrested vascular repair after injury. In contrast, the adeno-associated virus 9–mediated re-expression of an active CSE mutant retained p53 in the cytosol, maintained endothelial glucose metabolism and proliferation, and prevented endothelial cell senescence. Adenoviral overexpression of CSE in native endothelial cells from aged individuals maintained low p53 activity and reactivated telomerase to revert endothelial cell senescence. CONCLUSIONS: Aging-associated impairment of vascular repair is partly determined by the vasoprotective enzyme CSE.
Indocyanine green clearance tests to assess liver transplantation outcomes: a systematic review
Authors: Miriam Caimano, Giuseppe Bianco, Alessandro Coppola, Giuseppe Marrone, Salvatore Agnes, Quirino Lai, Gabriele Spoletini
Journal: International Journal of Surgery (2023)

Background: Liver transplantation (LT) is the gold standard for end-stage liver disease, yet postoperative complications challenge patients and physicians. Indocyanine green (ICG) clearance, a quantitative dynamic test of liver function, is a rapid, reproducible, and reliable test of liver function. This study aimed to systematically review and summarize current literature analyzing the association between ICG tests and post-LT outcomes. Methods: This systematic review was conducted according to PRISMA guidelines. MEDLINE and Cochrane Library, as main databases, and other sources were searched until August 2022 to identify articles reporting the prognostic value of postoperative ICG tests associated with outcomes of adult LT recipients. Risk of bias (ROB) of included articles was assessed using Quality In Prognosis Studies tool. Methodological quality varied from low to high across ROB domains. Results: Six studies conducted between 1994 and 2018 in Europe, America, and Asia were included. The study population ranged from 50 to 332 participants. ICG clearance on the first postoperative day was associated with early allograft dysfunction (EAD), graft loss, 1- and 3-mo patient survival probability, prolonged intensive care unit (ICU), and hospital stay. The dichotomized ICG plasma disappearance rate (PDR) provided a strong association with medium- and long-term outcomes: PDR&lt;10%/min with 1-month mortality or re-transplantation (Odds Ratio (OR): 7.89, 95% confidence interval (CI) 3.59-17.34, P &lt;0.001) and PDR&lt;16.0%/min with 3-month patient survival probability (Hazard ratio (HR): 13.90, 95% CI 4.67–41.35, P &lt;0.01). The preoperative model for end-stage liver disease and body mass index were independent prognostic factors for EAD, early complications, and prolonged ICU stay; post-LT prothrombin time and INR were independently associated with graft loss and bilirubin with a prolonged hospital stay. Conclusion: This review shows that ICG clearance tests are associated with graft function recovery, suggesting that a potential prognostic role of ICG test, as an aid in predicting the post-LT course, could be considered.